10 results
DEFA14A
AEON
AEON Biopharma Inc. - Ordinary Shares
14 May 24
Additional proxy soliciting materials
9:14am
, and in most European Union countries, the sponsor is liable to provide ‘no fault’ compensation to any study subject injured in the clinical study.
Prior
8-K
EX-10.1
zxj1n0vgomu50
12 Feb 21
Priveterra Acquisition Corp. Announces Pricing of Upsized $240 Million Initial Public Offering
4:31pm
- Prev
- 1
- Next